Thursday, October 12, 2023 - Agenda

Objective #1: Review current classification system for pulmonary hypertension (PH) with an emphasis on rare types which require specialized referral.

Objective #2: Review key elements of workup which often separate pulmonary arterial hypertension from other types of PH.

Objective #3: Briefly review modern approaches to therapy and risk stratification of patients with pulmonary arterial hypertension (PAH).

Robert Schilz, DO, PhD, Associate Professor of Medicine Case University, Cleveland, OH

Objective #1: Discuss the basics of a healthy life, factors that motivate us to exercise.

Objective #2: Discuss how to stick to your healthy habits, how to make it a lifestyle.

Objective #3: Discuss mindfulness, and relaxation as a crucial part of your fitness/wellness journey - it's not always about powering up but powering down and recovering too.

Joanne Kaiser-Smith, DO, FACOI (President), Associate Dean

Damon L. Baker, DO, FACOI (Program Chair), Professor and Chair

Tony Horton, Founder, Power Life by Tony Horton

Objective #1: Define microbiome;

Objective #2: Understand pathophysiology of dysbiosis;

Objective #3: Understand the potential manifestations of untreated dysbiosis

Charlene A. LePane, DO, FACOI, Gastroenterologist, AdventHealth

Objective #1: To review and discuss latest guidelines regarding COVID and seasonal influenza vaccinations

Objective #2: To review updated vaccination guidelines for routine adult vaccines

Objective #3: To discuss additional vaccine recommendations for certain higher risk travel abroad

Mia A. Taormina, DO, FACOI, Chair, Department of Infectious Disease, Duly Health and Care

Objective #1: Identify patients with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis and initiate therapies that can reduce risk of serious liver damage.

Objective #2: Describe treatment options for managing patients with metabolic-associated fatty liver disease.

Objective #3: Summarize lifestyle and dietary interventions that can be key factors associated with successfully reducing risk in patients with NAFLD

Robert P. Aran, DO, Chief Fellow, Oklahoma State University (Tulsa)

NON-CME Sponsored by AstraZeneca. Session details coming soon.

Miguel K. Lob, PharmD

Objective #1: Discuss gout risk factors and diagnosis.

Objective #2: Understand gout management strategies individualized to the person: A three pronged approach: urate lowering therapy, anti-inflammatories and risk mitigation.

Objective #3: Recognize that gout is a chronic condition that can lead to extra-articular manifestations with long-term complications/co-morbidities.

Priyanka A. Murali, DO, FACOI, Rheumatology Site Director, C.W. Bill Young VA Medical Center

Objective #1: Discuss ongoing research in the field of spondyloarthropathies and the microbiome.

Objective #2: Describe unique findings of the gut microbiome in those with diagnosed spondyloarthropathies.

Objective #3: Design a care plan that incorporates an integrative approach to the treatment of those with spondyloarthropathies.

Mary E. Hinojos Mamut, DO, Rheumatology Board Certified (AOBIM & ABIM), Mercy Clinic

Objective #1: To understand the fundamentals of inflammation and its impact on human health: This objective aims to provide participants with a comprehensive understanding of inflammation, its causes, and its effects on various body systems. The lecture will cover the mechanisms of inflammation and the role of chronic inflammation in the development of diseases.

Objective #2: To explore the concept of anti-inflammatory diets: This objective focuses on introducing participants to the concept of anti-inflammatory diets and their potential benefits. The lecture will provide an overview of foods that have anti-inflammatory properties. The objective is to empower individuals with knowledge about dietary choices that can help reduce inflammation and support optimal health.

Objective #3: To provide practical information for implementing an anti-inflammatory diet/lifestyle. The objective is to enable participants to make informed dietary choices and embrace a long-term anti-inflammatory lifestyle.

Monica D. Shah, DO, Teaching Faculty, Rheumatology Fellowship Program Bayonet Point Hospital via HCA Healthcare Florida/University of South Florida Hudson, FL

Objective #1: Recognize the four classes of guideline-directed medical therapies indicated for patients with heart failure and be comfortable initiating and titrating them.

Objective #2: Identify patients who need to be referred to a heart failure and transplant cardiologist for consideration of advanced therapies such as heart transplants and left ventricular assist devices.

Objective #3: Understand that disparities exist across the spectrum of heart failure from prevention of heart failure to allocation of organs in heart transplantation.

Nasrien Ibrahim, MPH, MD, Advanced Heart Failure and Transplant Cardiologist

Objective #1: Defining Obesity from its clinical perspective

Objective #2: Appreciating the pathophysiology of Obesity in terms of Dysadiposity and its relevance to other chronic disease states.

Objective #3: Reviewing the Pharmacologic Treatment Strategies currently available for Dysadiposity

Eric S. Langer, DO, FACOI, Program Director, Endocrinology Fellowship Training Program

Objective #1: Understand lab testing in adrenal insufficiency diagnosis.

Objective #2: Understand adrenal biopsy contraindications.

Objective #3: Understanding Lab testing is Cushing Syndrome diagnosis.

John R. Sutton, DO, MACOI, American College of Osteopathic Internists, Past President

Objective #1: 1. Discuss the stages of Type 1 Diabetes Mellitus

Objective #2: 2. Review use of teplizumab-mzwv new medical therapy to delay the onset of Type 1 Diabetes Mellitus

Objective #3: 3. Discuss how technology can impact the management of Type 1 Diabetes Mellitus

Erica M. Kretchman, DO, Endocrinologist